Antje Schmidt

Title: Antje Schmidt: Innovator in Antibody Research

Introduction

Antje Schmidt is a prominent inventor based in Göttingen, Germany. She has made significant contributions to the field of antibody research, particularly focusing on human Semaphorin 3A (Sema3A). With a total of 2 patents to her name, her work has the potential to impact various therapeutic applications.

Latest Patents

Antje Schmidt's latest patents include innovative developments in anti-Sema3A antibodies. The first patent discloses an isolated antibody or antigen-binding fragment that specifically binds to human Sema3A. This patent also includes an antibody conjugate and a pharmaceutical composition that utilizes the isolated antibody. The second patent further elaborates on the characteristics of the isolated antibody, detailing its binding affinity and cross-reactivity with Sema3A from various species, including mouse and rat. It also highlights the antibody's ability to inhibit the activity of human Sema3A in multiple in vitro assays.

Career Highlights

Antje Schmidt is currently employed at Bayer Aktiengesellschaft, where she continues her research and development in the field of antibodies. Her work is crucial in advancing the understanding of Sema3A and its implications in various biological processes.

Collaborations

Antje collaborates with notable colleagues, including Dorian Schönfeld and Karoline Dröbner, who contribute to her research endeavors. Their combined expertise enhances the innovative potential of their projects.

Conclusion

Antje Schmidt's contributions to antibody research, particularly in the area of Sema3A, demonstrate her commitment to innovation in the field. Her patents reflect a significant advancement in therapeutic possibilities, showcasing her role as a leading inventor in this domain.